Clinical Trials in Vienna, Virginia
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
Hypertension (HTN)
Sarfez Pharmaceuticals, Inc.30 enrolled1 locationNCT07223502
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.500 enrolled80 locationsNCT06433752
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Phase 2
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Cytokinetics60 enrolled24 locationsNCT06793371
Recruiting
Phase 2
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Uncontrolled Hypertension
Retension Pharmaceuticals. Inc.280 enrolled3 locationsNCT07142356
Recruiting
Phase 2
Study of JK07 in Patients With Chronic Heart Failure
Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc282 enrolled62 locationsNCT06369298